Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

FDA Approves Amivantamab-vmjw with Carboplatin and Pemetrexed for Non-Small Cell Lung Cancer with EGFR Exon 19 Deletions or L858R Mutations

Evidence for efficacy is based on the results from the MARIPOSA-2 study
29 Oct 2024
Targeted Therapy;  Molecular Oncology;  Cytotoxic Therapy
Non-Small Cell Lung Cancer

On 19 September 2024, the US Food and Drug Administration (FDA) approved amivantamab-vmjw (Rybrevant, Janssen Biotech, Inc.) with carboplatin and pemetrexed for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) Exon 19 deletions or Exon 21 L858R substitution mutations whose disease has progressed on or after treatment with an EGFR tyrosine kinase inhibitor.

Efficacy was evaluated in MARIPOSA-2 (NCT04988295), a randomised, open-label, multicentre study in 657 patients with locally advanced or metastatic NSCLC with EGFR Exon 19 deletions or Exon 21 L858R substitution mutations and disease progression on or after receiving osimertinib. Patients were randomised (1:2:2) to receive amivantamab-vmjw with carboplatin and pemetrexed (amivantamab plus CP), carboplatin and pemetrexed (CP), or amivantamab-vmjw as part of another combination regimen.

The major efficacy outcome measure was progression-free survival (PFS) as assessed by blinded independent central review (BICR) for the comparison between amivantamab plus CP and CP. Overall response rate (ORR) per BICR and overall survival (OS) were key secondary outcome measures. Median PFS was 6.3 months (95% confidence interval [CI] 5.6, 8.4) in the amivantamab plus CP arm and 4.2 months (95% CI 4.0, 4.4) in the CP arm (hazard ratio [HR] 0.48, 95% CI 0.36, 0.64, p-value < 0.0001). The confirmed ORR was 53% (95% CI 44, 62) in the amivantamab plus CP arm and 29% (95% CI 23, 35) in the CP arm (p-value < 0.0001).

At the prespecified second interim analysis of OS, with 85% of the deaths needed for the final analysis, there was no statistically significant difference in OS. The stratified HR for OS was 0.73 (95% CI 0.54, 0.99).

The most common adverse reactions (≥20%) were rash, infusion-related reactions, fatigue, nail toxicity, nausea, constipation, oedema, stomatitis, decreased appetite, musculoskeletal pain, vomiting, and COVID-19 infection.

The recommended amivantamab-vmjw dose is based on baseline body weight. See the prescribing information for specific dosage information.

This review was conducted under Project Orbis, an initiative of the FDA’s Oncology Center of Excellence (OCE). Project Orbis provides a framework for concurrent submission and review of oncology drugs among international partners. For this review, FDA collaborated with the Australian Therapeutic Goods Administration, the Brazilian Health Regulatory Agency, and Health Canada. The application reviews are ongoing at the other regulatory agencies.

This review used the Assessment Aid, a voluntary submission from the applicant to facilitate the FDA’s assessment. submission from the applicant to facilitate the FDA’s assessment.

Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA’s MedWatch Reporting System.

For assistance with single-patient INDs for investigational oncology products, healthcare professionals may contact OCE’s Project Facilitate.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.